

JUN 20 1996

Mr. Thomas H. Prickett
President
Suburban General Hospital
100 South Jackson Avenue
Pittsburgh, PA 15202-3499

Dear Mr. Prickett

In accordance with 10 CFR 35.14, your letter received June 11, 1996 is accepted as notification that you have permitted Karen Barkey, M.D. and Fayegh Jadali, M.D., Ph.D. to work as an authorized user pursuant to 10 CFR 35.13(b)(1). Also in accordance with 10 CFR 35.14, the letter received June 11, 1996, is accepted as notification that Stanley J. Grossman, M.D. is no longer practicing at your facility. These corrections to your license will be updated at your next license renewal. No further correspondence on this matter is required.

Your cooperation is appreciated.

Sincerely,

Tara L. Weidner
Division of Nuclear Materials Safety

License No. 37-15350-01
Docket No. 030-08957
Control No. 123324

Enclosure:
10 CFR Part 35

DOCUMENT NAME: R:\WPS\MLTR\L3715350


To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	N	DNMS/RI				
NAME	TWeidner/tlw						
DATE	06/18/96	06/	/96	06/	/96	06/	/96

OFFICIAL RECORD COPY

ML 10

9610110358 960620
PDR ADOCK 03008957
C PDR



U.S. Nuclear Regulatory Commission
Region I
Nuclear Materials Section B
King of Prussia, PA 19406
June 4, 1996

FOR NOTIFICATION ONLY

Re: NRC License No. 37-15350-01

Gentlemen:

This is to notify you as per 10CFR 35.14 that we are permitting Karen Barkey, M.D. and Fayegh Jadali, M.D., PhD. to use radioactive materials for medical applications as authorized under subparts D, E, and F of 10CFR 35. Dr. Barkey is currently an authorized user for such applications on NRC License No. 37-06575-03 belonging to Monongahela Valley Hospital, PA. Enclosed is a copy of the license from Monongahela Valley Hospital indicating Dr. Barkey's authorized uses. Enclosed is a copy of Dr. Jadali's certification by the American Board of Nuclear Medicine and his preceptor statement.

Also, please delete Stanley J. Grossman, M.D. from our license.
Thank you.

Sincerely yours,

Thomas H. Prickett
President

Enc: Monongahela Valley Hospital NRC License No. 37-06575-03
Copy of Dr. Jadali's preceptor statement and ABNM
certification

Where Caring Is A Tradition

123324

NRC FORM 374
(7-94)

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 3 PAGES

MATERIALS LICENSE

Amendment No. 29

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Monongahela Valley Hospital, Inc.</p> <p>2. Country Club Road Monongahela, Pennsylvania 15063</p>	<p>In accordance with the letter dated May 19, 1995,</p> <p>3. License Number 37-06575-03 is amended in its entirety to read as follows:</p> <p>4. Expiration Date August 31, 1999</p> <p>5. Docket or Reference No. 030-07584</p>	
<p>6. Byproduct, Source, and/or Special Nuclear Material</p> <p>A. Any byproduct material identified in 10 CFR 35.100</p> <p>B. Any byproduct material identified in 10 CFR 35.200</p> <p>C. Any byproduct material identified in 10 CFR 35.300</p> <p>D. Any byproduct material identified in 10 CFR 35.400</p> <p>E. Any byproduct material identified in 10 CFR 35.500</p> <p>F. Any byproduct material identified in 10 CFR 31.11</p> <p>G. Cesium 137</p>	<p>7. Chemical and/or Physical Form</p> <p>A. Any radiopharmaceutical identified in 10 CFR 35.100</p> <p>B. Any radiopharmaceutical identified in 10 CFR 35.200</p> <p>C. Any radiopharmaceutical identified in 10 CFR 35.300</p> <p>D. Any brachytherapy source identified in 10 CFR 35.400</p> <p>E. Any diagnostic source identified in 10 CFR 35.500</p> <p>F. Prepackaged Kits</p> <p>G. Sealed Sources (CEA/DRIS CSM-3)</p>	<p>8. Maximum Amount that Licensee May Possess at Any One Time Under This License</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. As needed</p> <p>D. 3,000 millicuries</p> <p>E. As needed</p> <p>F. As needed</p> <p>G. Not to exceed 150 millicuries per source and 1 curie total</p>
<p>9. Authorized use</p> <p>A. Any uptake, dilution and excretion procedure approved in 10 CFR 35.100.</p> <p>B. Any imaging and localization procedure approved in 10 CFR 35.200.</p> <p>C. Any radiopharmaceutical therapy procedure approved in 10 CFR 35.300.</p> <p>D. Any brachytherapy procedure approved in 10 CFR 35.400.</p> <p>E. Medical use of sealed sources included in 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).</p> <p>F. <u>In vitro</u> studies.</p> <p>G. For use in a Syncor Curiatron 2E1000 remote low dose rate brachytherapy unit for human therapy.</p>		

123324

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

37-06575-03

Docket or Reference number

030-07584

Amendment No. 29

CONDITIONS

10. Licensed material may be used only at the licensee's facilities at Country Club Road, Carroll Township, Monongahela, Pennsylvania.
11. The Radiation Safety Officer for this license is Michael J. Semon, M.S.
12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized UsersMaterial and Use

William E. Reisinger, Jr., M.D.

35.100; 35.200; 35.300; 35.500

In vitro studies

Vincente Alcantara, M.D.

35.100; 35.200; 35.300; 35.500

In vitro studies

Vallabhaneni Babu, M.D.

35.100; 35.200; 35.500

In vitro studies

Richard Gnegy, M.D.

35.100; 35.200; Iodine 131 for the treatment of hyperthyroidism and cardiac dysfunction

In vitro studies

Robert Peard, M.D.

35.100; 35.200; 35.500

In vitro studies

Jennifer Bender, M.D.

35.100; 35.200; 35.500

In vitro studies

Peter M. Bonadio, M.D.

35.100; 35.200

In vitro studies

Gerald Medwick, D.O.

35.400

Julian W. Proctor, M.D.

35.400

Tarit Kanti Dutta, M.D.

35.400

Anthony Hovenden, M.D.

35.400

Carlos Torres, M.D.

35.400

Karen J. Barkey, M.D.

35.100; 35.200; 35.300

In vitro studies

123324

NRC Form 374A
(5-84)

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 OF 3 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

37-06575-03

Docket or Reference number

030-07584

Amendment No. 29

- 13.A. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d), 40.36(b), and 70.25(d) for establishing financial assurance for decommissioning.
- B. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material at a single location to quantities below the limits specified in 10 CFR 30.72 which require consideration of the need for an emergency plan for responding to a release of licensed material.
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated March 31, 1994
- B. Letter dated June 14, 1994
- C. Letter dated July 8, 1994
- D. Letter dated May 19, 1995
- E. Letter dated July 31, 1995



For the U.S. Nuclear Regulatory Commission

By

Nuclear Materials Safety Branch

Region I

King of Prussia, Pennsylvania 19406

Date SEP 12 1995

PRECEPTOR STATEMENT (Continued)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION	COMMENTS (Additional information or explanation may be submitted by clipboard on separate sheet.)
A	B	C	D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES	✓	
P-32 (Colloid)	INTRACAVITARY TREATMENT	2	
I-131	TREATMENT OF THYROID CARCINOMA	10	
	TREATMENT OF HYPERTHYROIDISM	30	
Au-198	INTRACAVITARY TREATMENT	✓	
Co-60 or Cs-137	INTERSTITIAL TREATMENT	✓	
	INTRACAVITARY TREATMENT	✓	
I-125 or I-127 Co-60 or Cs-137	INTERSTITIAL TREATMENT	✓	
	TELETHERAPY TREATMENT	✓	
Sr-90	TREATMENT OF EYE DISEASE	✓	
	RADIOPHARMACEUTICAL PREPARATION	✓	
Mo-99/ Tc-99m	GENERATOR	10	
Sn-113/ In-113m	GENERATOR	✓	
Tc-99m	REAGENT KITS	60	
Other			

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

Completed 2 year residency in Nuclear Medicine 7/1/92 thru 6/30/94
(2) x 45 hrs/wk x 48 wks/yr = 4320 hrs

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR

ALAN H. MAURER, M.D.

b. NAME OF INSTITUTION

Temple University Hospital

c. MAILING ADDRESS

Broad & Ontario Streets


d. CITY

Phila, PA 19140

e. MATERIALS LICENSE NUMBER(S)

87-0697-31

6. PRECEPTOR'S SIGNATURE



7. PRECEPTOR'S NAME (Please type or print)

ALAN H. MAURER

8. DATE

5/6/96

FORM NRC-313M-SUPPLEMENT B
(8-78)

U. S. NUCLEAR REGULATORY COMMISSION

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. APPLICANT PHYSICIAN'S NAME AND ADDRESS

FULL NAME

Fayesh J. Jafari

STREET ADDRESS

8388 Knollwood Dr.

CITY

STATE ZIP CODE

Allison Park, PA. 15101

KEY TO COLUMN C

PERSONAL PARTICIPATION SHOULD CONSIST OF:

1. Supervised examination of patients to determine the suitability for radiotracer diagnosis and/or treatment and recommendation for prescribed dosage.

2. Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of dose.

3. Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.)
A	B	C	D
I-131 or I-125	DETERMINATION OF THYROID FUNCTION	40	
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME		
	LIVER FUNCTION STUDIES		
	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES	5	
	IN VITRO STUDIES		
OTHER			
I-125	DETECTION OF THROMBOSIS		
I-131	THYROID IMAGING	200	
P-32	EYE TUMOR LOCALIZATION		
Sm-75	PANCREAS IMAGING		
Yb-109	CISTERNOGRAPHY		
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES	500	
OTHER			
Tc-99m	BRAIN IMAGING	100	
	CARDIAC IMAGING	200	
	THYROID IMAGING	20	
	SALIVARY GLAND IMAGING	2	
	BLOOD POOL IMAGING	50	
	PLACENTA LOCALIZATION	—	
	LIVER AND SPLEEN IMAGING	20	
	LUNG IMAGING	400	
	BONE IMAGING	1500	
OTHER			

FORM NRC-313M-SUPPLEMENT A (8-78)		U.S. NUCLEAR REGULATORY COMMISSION		
TRAINING AND EXPERIENCE AUTHORIZED USER OR RADIATION SAFETY OFFICER				
1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER <div style="font-size: 1.2em; font-family: cursive;">Fayegh Tadali</div>			2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE <div style="font-size: 1.2em; font-family: cursive;">PA</div>	
3. CERTIFICATION				
SPECIALTY BOARD <div style="text-align: center;">A</div>	CATEGORY <div style="text-align: center;">B</div>	MONTH AND YEAR CERTIFIED <div style="text-align: center;">C</div>		
ABNM		9/94		
4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES				
FIELD OF TRAINING <div style="text-align: center;">A</div>	LOCATION AND DATE(S) OF TRAINING <div style="text-align: center;">B</div>	TYPE AND LENGTH OF TRAINING		
		LECTURES/ LABORATORY COURSES <div style="text-align: center;">(Hours) C</div>	SUPERVISED LABORATORY EXPERIENCE <div style="text-align: center;">(Hours) D</div>	
a. RADIATION PHYSICS AND INSTRUMENTATION	Temple University Hospital Dept. of Nuclear Medicine 7/1/92 - 6/30/94	110	40	
b. RADIATION PROTECTION	"	25		
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	"	15		
d. RADIATION BIOLOGY	"	30		
e. RADIOPHARMACEUTICAL CHEMISTRY	"	20	40	
5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)				
ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE
Tc-99m	30mCi	Temple University Hospital	7/1/92 - 6/30/94	Diagnostic Imaging
Tl-201	40mCi	"	"	"
In-111	500uCi	"	"	"
Ga-67	15mCi	"	"	"
Xe-133	20mCi	"	"	"
Tl-203	5mCi	"	"	"
I-131	200mCi	"	"	Thyroid Cancer Therapy

The American Board of Nuclear Medicine

Incorporated 1971


Certifies that


Fayegh Hadali

has met the requirements of this Board and is qualified
during the period 1994 through 2004 to practice as a Specialist
in all aspects of Clinical and Laboratory

Nuclear Medicine


including but not limited to Radiobioassay, Nuclear Imaging,
In Vivo Measurements & Therapy with Unsealed Radionuclides


chairman



05935

Number 3


Secretary

(FOR LFMS USE)
INFORMATION FROM LTS

```
: PROGRAM CODE: 02120  
: STATUS CODE: 0  
: FEE CATEGORY: 7C  
: EXP. DATE: 20011031  
: FEE COMMENTS:  
: DECOM FIN ASSUR REQD: N
```

A. REGION

APPLICANT/LICENSEE: SUBURBAN GENERAL HOSPITAL
RECEIVED DATE: 960611
DOCKET NO: 3008957
CONTROL NO.: 123324
LICENSE NO.: 37-15350-01
ACTION TYPE: NOTIFICATIONS

AMOUNT: _____
CHECK NO.: _____

SIGNED M. A. Terhune
DATE 6/12/96

1. FEE CATEGORY AND AMOUNT: -----

AMENDMENT _____
RENEWAL _____
LICENSE _____

SIGNED _____
DATE _____